Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Enfortumab Vedotin Approved in Europe for Locally Advanced or Metastatic Urothelial Cancer

April 13th 2022

The European Commission has approved enfortumab vedotin for use as a single agent in adult patients with locally advanced or metastatic urothelial cancer who have received prior platinum-containing therapy and a PD-1/L1 inhibitor.

Dr. Ornstein on the Benefit of Neoadjuvant Therapy in RCC

April 13th 2022

Moshe Ornstein, MD, MA, discusses the benefit of neoadjuvant therapy in renal cell carcinoma.

Dr. Iacovelli on Eligibility Criteria of the ARIES Trial in Urothelial Cancer

April 13th 2022

Roberto Iacovelli, MD, PhD, discusses the patient eligibility criteria of the phase 2 ARIES trial in urothelial cancer.

Pembrolizumab Plus CG0070 Induces Promising Response Rates in BCG-Unresponsive NMIBC

April 13th 2022

The addition of the selective oncolytic adenovirus CG0070 to pembrolizumab showed encouraging activity and safety in Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer, according to early data from the phase 2 CORE1 trial.

NICE Makes Avelumab Available for Maintenance Treatment of Urothelial Cancer

April 8th 2022

Avelumab is now a treatment option for patients with urothelial cancer in the United Kingdom following a recommendation from the National Institute for Health and Care Excellence issued Thursday, April 7, 2022.1

Adjuvant Nivolumab Approved in Europe for Select High-Risk Muscle-Invasive Urothelial Carcinoma

April 5th 2022

The European Commission has approved nivolumab for use in the adjuvant treatment of adult patients with muscle-invasive urothelial carcinoma and a PD-L1 expression of 1% or higher on tumor cells, who are at a high risk of recurrence following radical resection.

Nab-Paclitaxel Plus Pembrolizumab Produces Promising Responses in Advanced Urothelial Cancer

March 22nd 2022

Nab-paclitaxel plus pembrolizumab produced an encouraging overall response rate with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or cisplatin ineligible, according to data from the phase 2 ABLE trial.

Dr. Iacovelli on Next Steps of the ARIES Trial in Urothelial Cancer

March 15th 2022

Roberto Iacovelli, MD, PhD, discusses the potential next steps of the phase 2 ARIES trial in urothelial cancer.

Neoadjuvant Chemotherapy Benefit Retains Stronghold for Patients With MIBC, UTUC

March 15th 2022

Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.

Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC

March 14th 2022

Daniel P. Petrylak, MD, discusses the rationale for of the phase 1b/2 EV-103 trial in patients with muscle-invasive bladder cancer.

Immunotherapy and Targeted Treatment Approaches Improve Outcomes in Metastatic Urothelial Cancer

March 14th 2022

Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.

Dr. Ramnaraign on Sequencing IO and TKI Combinations in Metastatic RCC

March 8th 2022

Brian Ramnaraign, MD, discusses sequencing immunotherapy and tyrosine kinase inhibitor combinations in metastatic renal cell carcinoma.

EU Panel Confirms Recommendation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

February 28th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has confirmed its recommendation to approve the use of enfortumab vedotin in adult patients with locally advanced or metastatic urothelial cancer who have received prior platinum-based chemotherapy and a PD-1/PD-L1 inhibitor.

Dr. Iacovelli on the Rationale of the ARIES Trial in Urothelial Cancer

February 25th 2022

Roberto Iacovelli, MD, PhD, discusses the rationale of the phase 2 ARIES trial in urothelial cancer.

Adjuvant Nivolumab Approaches EU Approval for Select High-Risk Muscle-Invasive Urothelial Carcinoma

February 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab for use as an adjuvant treatment in adult patients with muscle-invasive urothelial carcinoma with a PD-L1 expression of at least 1% on tumor cells, who are at a high risk of recurrence following radical resection.

Neoadjuvant Atezolizumab/Chemo Shows Encouraging Efficacy in Muscle-Invasive Bladder Cancer

February 24th 2022

The addition of atezolizumab to neoadjuvant gemcitabine and cisplatin generated a high rate of non–muscle-invasive downstaging following radical cystectomy, which correlated with improved relapse-free survival and overall survival in patients with muscle-invasive bladder cancer, according to data from a phase 2 trial.

Neoadjuvant Enfortumab Vedotin Demonstrates Encouraging Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

February 19th 2022

Enfortumab vedotin produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer who were not eligible for cisplatin.

ASCO GU 2022: Breaking Down Bladder Cancer Results With Drs. Jonathan Rosenberg and Guru Sonpavde

February 19th 2022

OncLive® speaks with Drs. Jonathan Rosenberg and Guru Sonpavde on the groundbreaking research being presented in bladder cancer.

Frontline Olaparib/Durvalumab Misses PFS End Point in Platinum-Ineligible Metastatic Urothelial Carcinoma

February 19th 2022

The addition of olaparib to durvalumab did not result in a significant prolongation in progression-free survival compared with durvalumab alone in patients with previously untreated, platinum-ineligible metastatic urothelial carcinoma.

Addition of Sacituzumab Govitecan to Pembrolizumab Produces Promising Antitumor Activity in Metastatic Urothelial Cancer

February 19th 2022

Second-line sacituzumab govitecan plus pembrolizumab generated promising antitumor activity in patients with checkpoint inhibitor–naïve metastatic urothelial cancer.